Latest Financials News

Centuria Industrial REIT reports robust Q3 leasing activity with over 102,000 sqm of lease terms agreed year-to-date and advances $60 million in development projects, reaffirming its FY25 earnings and distribution guidance.

Alliance Aviation Services has updated its FY25 financial guidance, aiming for EBITDA between $205-210 million while navigating operational disruptions and planning significant debt reduction by 2026.

Tartana Minerals has raised $1.55 million through a director-led unsecured loan facility and appointed Dr Alistair Lewis as its new Chairman, signaling a strategic push in exploration and project advancement.

Smartgroup Corporation Limited reported robust financial growth in 2024, driven by record customer numbers and a significant rise in electric vehicle leasing, positioning the company for a sustainable future.

Core Lithium has released a comprehensive Restart Study for its Finniss Lithium Project, outlining a transition to fully underground mining that extends the mine life to 20 years while slashing operating costs and boosting production capacity.

EBR Systems has won FDA approval for its pioneering leadless WiSE CRT System, setting the stage for a phased US commercial rollout. The company also secured key Medicare reimbursement pathways and expanded manufacturing capacity, though financial sustainability remains a concern.

Core Lithium's Restart Study for the Finniss Lithium Operation confirms a 20-year underground mine life with significant cost reductions and enhanced production capacity.

Core Lithium has doubled the Grants Ore Reserve by shifting to underground mining, lifting total Finniss Ore Reserves to 10.73 million tonnes at 1.29% lithium oxide. This update supports a robust 10-year mine plan with potential for extended operations.

QBE Insurance Group has announced plans to issue AUD subordinated notes as part of its capital management strategy, aiming to strengthen its Tier 2 capital base. Details on pricing and timing will follow, contingent on market conditions.

Aristocrat Leisure Limited reported a robust HY25 with revenue rising 9% to AUD 3 billion and a 6% increase in NPATA, underpinned by strategic acquisitions and operational resilience. The company signals confidence in sustained growth through innovation and market expansion.

Anteris Technologies has submitted its FDA Investigational Device Exemption for the pivotal PARADIGM Trial of its DurAVR heart valve and marked a milestone of 100 patients treated, while expanding manufacturing capacity amid rising R&D costs.

Anteris Technologies Global Corp. reported a $21.9 million net loss for Q1 2025, driven by increased R&D spending as it scales manufacturing and prepares pivotal trials for its DurAVR Transcatheter Heart Valve. The company’s recent $80 million IPO proceeds are being deployed to support these efforts and repay debt.